Cypherpunk Technologies INC. 8-K Filing

Ticker: CYPH · Form: 8-K · Filed: Dec 16, 2025 · CIK: 1509745

Cypherpunk Technologies INC. 8-K Filing Summary
FieldDetail
CompanyCypherpunk Technologies INC. (CYPH)
Form Type8-K
Filed DateDec 16, 2025
Pages4
Reading Time4 min
Key Dollar Amounts$0.001, $1.00
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Cypherpunk Technologies INC. (ticker: CYPH) to the SEC on Dec 16, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (registered Common Stock, par value $0.001 CYPH Nasdaq Capital Market Indicate); $1.00 (ce of the Common Stock had fallen below $1.00 per share for 30 consecutive business d).

How long is this filing?

Cypherpunk Technologies INC.'s 8-K filing is 4 pages with approximately 1,096 words. Estimated reading time is 4 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 1,096 words · 4 min read · ~4 pages · Grade level 11 · Accepted 2025-12-16 16:05:31

Key Financial Figures

Filing Documents

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Cypherpunk Technologies Inc. (f/k/a Leap Therapeutics, Inc.) (the "Company") held a special meeting of stockholders (the "Special Meeting") on December 15, 2025 at 11:00 a.m. EST. As described in Item 5.07 of this Current Report on Form 8-K, the Company's stockholders voted to approve the adoption of the Company's 2025 Equity Incentive Plan (the "2025 Plan") at the Special Meeting, and the 2025 Plan became immediately effective upon such approval. The 2025 Plan, among other matters, provides for a total of 31,454,785 shares of the Company's common stock, $0.001 par value per share ("Common Stock") that can be covered by grants, as may be adjusted from time to time on the terms described therein. A description of the 2025 Plan was set forth in the Company's definitive Proxy Statement filed with the Securities and Exchange Commission on November 3, 2025 (the "Proxy Statement") in the section titled "Proposal No. 3—Approval of the Leap Therapeutics, Inc. 2025 Equity Incentive Plan." The description of the 2025 Plan contained herein and in the Proxy Statement is qualified in its entirety by reference to the full text of the 2025 Plan, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference.

03 Amendments to Articles of Incorporation or Bylaws; Change

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. At the Special Meeting, the Company's stockholders approved an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation (the "Charter") to (i) increase the total number of shares that the Company is authorized to issue from 250,000,000 shares to 500,000,000 shares, of which 490,000,000 shares are designated as Common Stock, and 10,000,000 shares are designated as preferred stock, par value $0.001 per share, and (ii) include clarifying language regarding the applicability of recently amended provisions of Section 242 of the General Corporation Law of the State of Delaware ((i) and (ii) collectively, the "Charter Amendment"). The Charter Amendment was effected pursuant to a Certificate of Amendment to the Charter (the "Certificate of Amendment") filed with the Secretary of State of the State of Delaware on December 15, 2025 and was effective as of such date. The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed with this Current Report on Form 8-K as Exhibit 3.1 and is incorporated herein by reference.

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. (a)The Company held the Special Meeting on December 15, 2025. (b)The final voting results on each of the matters submitted to a vote of stockholders at the Special Meeting are set forth below: (1) The Company's stockholders voted to approve the authorized share increase proposal. Votes For Votes Against Votes Abstaining 29,990,904 4,121,627 18,538 (2) The Company's stockholders voted to approve the reverse stock split proposal. Votes For Votes Against Votes Abstaining 36,314,864 4,935,206 691,181 (3) The Company's stockholders voted to approve the Company's adoption of the 2025 Equity Incentive Plan. Votes For Votes Against Votes Abstaining 28,765,316 5,105,626 260,130 (4) The Company's stockholders eligible to vote on this matter voted to approve the private placement issuance proposal. Votes For Votes Against Votes Abstaining 17,403,379 1,361,238 154,144 (5) The Company's stockholders voted to authorize the adjournment of the Special Meeting. Votes For Votes Against Votes Abstaining 35,080,571 6,571,932 288,748

01 Other Events

Item 8.01 Other Events. As previously reported, on March 12, 2025, The Nasdaq Stock Market LLC ("Nasdaq") notified the Company that, because the closing bid price of the Common Stock had fallen below $1.00 per share for 30 consecutive business days, the Company no longer met the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). On September 10, 2025, Nasdaq granted the Company's request for an additional 180 calendar day period to regain compliance with the listing rule. On December 11, 2025, the Company received a letter from Nasdaq notifying the Company that it had regained compliance with Nasdaq Listing Rule 55520(a)(2), and the matter is now closed.

01 Financial Statements

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation of Cypherpunk Technologies Inc. 10.1 2025 Cypherpunk Technologies Inc. Equity Incentive Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYPHERPUNK TECHNOLOGIES INC. Dated: December 16, 2025 By: /s/ Douglas E. Onsi Name: Douglas E. Onsi Title: Chief Executive Officer and President

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing